logo
Plus   Neg
Share
Email

Big Lots Guides Q3 EPS Well Above Estimates - Quick Facts

Discount retailer Big Lots, Inc. (BIG) provided on Tuesday the expected results for the third quarter of fiscal 2020. The company estimates comparable sales will increase in the mid-teens for the quarter.

Based on this sales outlook, the company estimates it will generate earnings in a range of $0.50 to $0.70 per share for the third quarter. This guidance incorporates expected share repurchase activity for the quarter.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $0.21 per share for the quarter. Analysts' estimates typically exclude special items.

The company said a month ago that it is not in a position to re-instate its financial guidance for the full-year 2020 as it continues to believe it does not have sufficient visibility amidst the ongoing COVID-19 pandemic. It had withdrawn its financial guidance for the first quarter and full year 2020 in late March.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
TJX Companies Inc. is recalling about 92,000 outdoor wooden folding chairs for potential risk of fall and injury hazards, a statement by the U.S. Consumer Product Safety Commission showed. The company said the chairs can break and can pose fall and injury hazards to the user. The company has received 18 reports of the recalled chairs breaking or collapsing, including 15 reports of falls. German automaker Volkswagen AG on Thursday raised its forecast for fiscal 2021 operating margin after reporting a significant growth in first-quarter profit with strong revenues and deliveries. The company also projects significantly higher revenues and deliveries in the full year. Meanwhile, Volkswagen shares were losing around 2 percent in German trading. Biotechnology company Novavax, Inc. (NVAX) announced Thursday that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility. Under the APA, Novavax is expected to manufacture...
Follow RTT